CorVel reported Q3 2026 results with modest growth: revenue of $236 million (up 3% YoY) and EPS of $0.47 (up 2% YoY). The company highlighted strong operational metrics including 100% net revenue retention, 44% new business close rate, and meaningful AI-driven efficiency gains. Management attributed the modest results to short-term operational factors and tax normalization rather than fundamental business changes. The CERES division showed strong momentum in healthcare payment integrity services, with accelerated technology integration from a June acquisition. CorVel maintains a strong balance sheet with $230 million in cash, no debt, and continues share repurchases.

CorVel reported Q2 2026 financial results with $240 million revenue, a 7% increase from the previous year. The company highlighted significant investments in Agentic AI technology, workforce development through CorVel University, and strategic efforts to address labor market challenges in workers' compensation.

CorVel Corporation announced a three-for-one forward stock split, effective December 24, 2024. The additional shares will be distributed on the same date, and trading is expected to begin on a post-split basis on December 26, 2024.

CORXEL, a biotech company, has acquired the worldwide (excluding Greater China) rights to CX11, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity and diabetes. CX11 has shown promising results in a Phase 2 clinical trial conducted in China and CORXEL plans to initiate a global Phase 2 study in 2025.

CorVel Corporation announces the retirement of its founder and Chairman, V. Gordon Clemons, after 37 years of service. Michael G. Combs, the company's President and CEO, will succeed Clemons as the new Chairman.

Corstar Holdings Inc, a significant shareholder in Corvel Corp, has sold over $12.9 million worth of Corvel Corp shares between July 12 and July 16. The transactions were made pursuant to a Rule 10b5-1 trading plan.

CorVel, a healthcare technology company, reported insider selling activity. The company has shown positive revenue growth, strong earnings per share, and prudent debt management, but its valuation metrics suggest it may be overpriced.

FORT WORTH, Texas, May 22, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter and fiscal year ended March 31, 2024. Revenues for the quarter were $207 million, an increase from $185 million in the same quarter of the previous year. Earnings per share for the quarter were $1.12, compared to $1.04 in the same quarter of the prior year.

CorVel (NASDAQ: CRVL) unveils AI-driven managed care solutions, offering seamless integration and enhanced insights for partners, improving patient care.

CorVel provides cost-effective vocational evaluations nationwide, aiding injured employees' return to work with tailored solutions by certified experts

FORT WORTH, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDQ:CRVL), is proud to be Certified™ by Great Place To Work® for the 4th year in a row. The prestigious award is based entirely on what current employees say about their experience working at CorVel. Great Place To Work® is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation.

FORT WORTH, Texas, Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended December 31, 2023. Revenues for the quarter were $202 million, an increase from $179 million in the December quarter of 2022. Earnings per share for the quarter were $0.99, compared to $0.96 in the same quarter of the prior year.